patients with NSC type of lung cancer with high expression of EGFR who are candidates for erlotinib as second / third line of treatment;
patients with advanced pancreatic tumor who are candidates for complex gemcitabine and erlotinib treatment.
You may not be if
lack of histological diagnosis;
not a candidate for erlotinib;
pregnancy.
Clareo Health | C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).
